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Background {#sec010}
==========

An estimated 24.7 million people living with HIV reside in sub-Saharan Africa representing 70% of the global HIV burden, and over 90% of HIV-infected women reside in Africa \[[@pone.0201038.ref001]\]. Statistics for the United Republic of Tanzania report 690,000 women age 15 years and older with HIV infection, and a maternal to child transmission (MTCT) rate of 26% \[[@pone.0201038.ref002]\].

The interaction between nutrition and HIV infection is complex. Malnutrition and HIV, independently and synergistically, weaken the immune system leading to increased susceptibility to infection and poorer health outcomes \[[@pone.0201038.ref003], [@pone.0201038.ref004]\]. Pregnant and lactating HIV-infected women and their infants living in resource poor settings may be at risk for poorer HIV outcomes due to underlying food insecurity and increased nutrient needs during pregnancy and lactation \[[@pone.0201038.ref005], [@pone.0201038.ref006]\] Dietary deficiencies of both micro- and macro-nutrients have been described in these groups and have led to trials of both types of dietary supplements \[[@pone.0201038.ref003], [@pone.0201038.ref007]--[@pone.0201038.ref009]\].

Trials of micronutrient supplements in HIV-positive pregnant women have shown improvement in maternal and infant health outcomes \[[@pone.0201038.ref010], [@pone.0201038.ref011]\]. However, few randomized controlled trials have evaluated macronutrient supplementation in HIV-infected lactating women.

Nearly two-thirds of HIV-infected pregnant women in Dar es Salaam, Tanzania are energy deficient and nearly half are protein deficient \[[@pone.0201038.ref012]\], and in a recent pilot study we found that lactating HIV-infected women were also deficient in energy and protein intake \[[@pone.0201038.ref013]\]. We used these data to design a culturally acceptable protein-calorie supplement for a randomized-controlled trial to assess the impact of macronutrient supplementation on the health outcomes of HIV-infected breast-feeding mothers and their infants.

Methods {#sec011}
=======

Study design {#sec012}
------------

The study was designed as a randomized controlled trial to determine if a protein calorie macronutrient supplement (PCS) plus micronutrient supplement (MNS) improved health outcomes in HIV-infected lactating women and their infants compared to MNS alone.

Subjects {#sec013}
--------

HIV-infected women ≥18 years old in their last trimester of pregnancy were screened from April 2011 to July 2012 at 5 antenatal clinics (3 district hospitals, 2 local clinics) in Dar es Salaam, Tanzania during their last trimester. Eligibility required that the woman be free of acute illness, have a BMI ≥18.5 kg/m^2^ and intend to exclusively breastfeed her infant for at least 3 months. All women were required to be enrolled in anti-retroviral therapy (ART) programs for Prevention of Mother to Child Transmission of HIV infection (PMCT).

Baseline evaluation {#sec014}
-------------------

After informed consent, subjects in the third trimester were interviewed to obtain socio-demographic information including age, residence, financial and employment status of both the patient and her partner, highest level of education, income spent specifically on food, and number and ages of persons living in the same household. Phlebotomy was performed for CD4 count and albumin and all subjects had anthropometric evaluations, twenty-four hour dietary recall and food insecurity evaluations.

Anthropometric measurements {#sec015}
---------------------------

Weight (kg) and, height (recumbent length in infants) were determined following standard protocols and using calibrated instruments. Skin fold thicknesses (mm) at five different areas including the triceps, subscapular, suprailiac, abdomen, and thigh as well as circumferences (cm) around the mid-upper arm, waist, hip, and thigh were determined by one of 3 three trained observers using calibrated Lange skinfold calipers and a Gulick II, non-stretch, pliable tape measure \[[@pone.0201038.ref014]\].

Dietary recall {#sec016}
--------------

Trained research nutritionists or study nurses evaluated dietary intake using a multiple pass 24-hour dietary recall to list all beverages and foods consumed in the previous day \[[@pone.0201038.ref015]\]. Multiple passes by the interviewer probed for food preparation and missed food items; standardized food models were used to determine portion size. Energy and protein intakes were then calculated using the Tanzania Food Composition tables \[[@pone.0201038.ref016]\]. Nutritional education and counseling based on distinct World Health Organization (WHO) and Tanzanian Ministry of Health National Guidelines for HIV-positive women, was provided \[[@pone.0201038.ref017]\].

Food insecurity {#sec017}
---------------

All subjects were administered the Household Food Insecurity Access Scale (HFIAS), which was adapted from the Food and Nutritional Technical Assistance II Project (FANTA-2) to determine availability and accessibility of food in each woman's household \[[@pone.0201038.ref018]\]. An adapted questionnaire contained a total of nine yes or no questions followed by a "frequency-of-occurrence" question. Some questions inquired about the subject's perception of food vulnerability while other questions addressed the subject's behavioral responses due to food insecurity. Based on the answers given by the client, a score was assigned to each woman ranging from 0 (no insecurity) to 27 (maximum insecurity).

Laboratory studies {#sec018}
------------------

Phlebotomy was performed to confirm HIV infection and determine the CD4 count. Subjects were required to have two positive rapid HIV tests: Determine HIV-1/2 Ag/Ab (Alere, Chiba, Japan) and Uni Gold HIV-1/2 (Trinity Biotech, Bray, Ireland). Women who tested positive and were unaware of their current HIV status were provided ELISA results, CD4 results, appropriate counseling, referred to a Ministry of Health Care and Treatment Center (CTC) if not already under care and then entered in the study. Subjects with a discordant ELISA result (one positive, one negative) were not eligible and referred to a CTC for further testing.

Nutritional supplements {#sec019}
-----------------------

In the pilot study the daily dietary intakes of HIV-infected lactating subjects were compared to recommendations of the World Health Organization (WHO) to achieve a mean energy target of 2854 Kcal (which includes an additional 10% increase in energy for HIV infection) and protein target of 86 gm (based on 12% of calories) \[[@pone.0201038.ref013]\]. Subjects were found to have a median daily dietary energy deficit 2 weeks after delivery of 517 Kcal and a mean daily dietary protein deficit of 29 gm; mean deficits at 6 weeks were 686 Kcal and 36 gm \[[@pone.0201038.ref019]--[@pone.0201038.ref023]\]. Subjects in the pilot study then participated in focus groups to test the palatability and acceptability several potential protein-calorie supplements (PCS). The supplement that was chosen for the present study was a porridge (Dar-uji) manufactured from locally available ingredients including flour (maize, soybeans, sorghum and millet), full cream dried milk, and sugar (Jamahedo Health Foods, Arusha, Tanzania). The PCS was provided in daily packets containing 1062 Kcal and 42 gm protein, amounts that would cover the 75^th^ percentile of deficits observed in the pilot study. Thirty packets of PCS were given to participants every four weeks. Each 250 mg packet was to be mixed with boiling water and consumed over the course of one day. The micronutrient supplement (MNS) was the standard combination of vitamins and minerals provide to patients with HIV infection by the Ministry of Health of Tanzania (Tishcon Corporation, Salsbury, MD). MNS consisted of 1.4mg thiamine, 1.4 mg riboflavin, 18 mg niacin, 1.9 mg vitamin B-6, 2.6 mg vitamin B-12, 70 ug vitamin C, 10 mg vitamin E and 0.4 mg folic acid \[[@pone.0201038.ref024]\]. All mothers also received 60 mg ferrous sulfate orally (PO) once daily and 1 mg folic acid PO once daily during pregnancy

Randomization and intervention {#sec020}
------------------------------

A randomization list was generated by the a study statistician and provided to the study team. Consecutive eligible subjects were randomized 1:1 in block sizes of 4 and 6 to receive the intervention (PCS plus MNS) or control (MNS alone). Subjects were provided with a four week supply. In addition subjects in the PCS intervention group were also given a supply of PCS packets so that 280 Kcal/day was provided for every child less than age 7 years living in the household with the subject.

Maternal follow-up {#sec021}
------------------

All mothers were seen monthly after enrollment in the third trimester at the study clinic, then at home 2--4 weeks after birth, and again at the study clinic monthly for 6 months after infant birth and again at 9 and 15 months after infant birth. At each visit thru 6 months subjects were provided with the supplements, had anthropometric evaluation, and a 24-hour dietary recall. ART use and clinical history were recorded. Laboratory tests including CD4 count were obtained and breast milk samples collected 2--4 weeks after delivery and again 3 months after delivery. Breast milk analysis will be the subject of a separate report.

Infant follow-up {#sec022}
----------------

All infants were examined at the initial home visit and then seen monthly for 6 months, again at 9 months and at 15 months for a medical history and measurement of weight and length. ART use and clinical history were recorded. At 15 months phlebotomy was performed per protocol to perform a single rapid HIV test, Uni Gold HIV-1/2 (Trinity Biotech, Bray, Ireland). Results of HIV testing that had been performed outside the study at government clinics were recorded, typically on infants who had been ill or died. or on infants who had been found to be HIV positive per protocol at 15 months. This testing included results of dried blood spot (DBS) HIV PCR testing at Tanzania Ministry of Health (MOH) HIV clinics where such testing is recommended at 2--3 months for all infants born to HIV-positive mothers. Hospital records were requested on infants who died as inpatients during the study.

Ethical approval {#sec023}
----------------

The study was approved by the Institutional Review Board at Geisel School of Medicine and the Research Ethics Committee of the Muhimbili University of Health and Allied Sciences (MUHAS).

Sample size, endpoints, and statistical analysis {#sec024}
------------------------------------------------

The primary endpoint for the trial was infant weight at 3 months. A sample size of 96 subjects, 48 subjects in each group, was calculated based on type 1 and 2 error rates of 5% and 20% respectively, a minimally clinically effect size of 0.5 kg, assuming that the standard deviation of weight at 2 months among HIV infected infants born on the African continent is approximately 0.7 kg (IQR = 4.0 to 4.9 kg. \[[@pone.0201038.ref025]\].

The primary endpoint, infant weight at 3 months, was compared between the two study arms using a two-sample t-test.

The secondary endpoint was maternal BMI 6 months after delivery. Maternal BMI (as well as weight and mid upper arm circumference) at 6 months post-delivery was compared between the two study arms using a linear model that controlled for maternal BMI at baseline. Laboratory parameters including maternal CD4 were compared in the same manner. Dietary intakes were compared between the two arms at specific time points using t-tests. Infant mortality was compared between the two study arms using Fisher's exact test. The incidence of infant HIV infection as determined by DBS at 2 months or HIV ELISA at 15 months was compared between the study arms using Fisher's exact test and also a log rank test that censored follow-up at 18 months or death. The main analyses included all mothers and infants. As a sensitivity analysis we repeated analyses excluding mothers of twins, and twins.

Results {#sec025}
=======

Patient characteristics {#sec026}
-----------------------

A total of 119 subjects were screened and 96 enrolled in the study during their third trimester between April 21, 2011--July 9, 2012 ([Fig 1](#pone.0201038.g001){ref-type="fig"}). Subjects were randomized 1:1 to the 2 intervention groups. Baseline characteristics, including anthropometry and food insecurity, did not differ between the two groups ([Table 1](#pone.0201038.t001){ref-type="table"}).

![Consort diagram.](pone.0201038.g001){#pone.0201038.g001}

10.1371/journal.pone.0201038.t001

###### Baseline subject characteristics in third trimester.

![](pone.0201038.t001){#pone.0201038.t001g}

  --------------------------------------------------------------------------------------------------
                                                                     MNS                 PCS +MNS
  ------------------------------------------------------------------ ------------------- -----------
  Mean age, years                                                    31                  31

  Education, N (%)                                                                       

      None                                                           3 (7%)              6 (13%)

      Some primary                                                   5 (11)              1 (2)

      Primary                                                        26 (57)             30 (63)

      Secondary                                                      3 (7)               3 (6)

      Higher than secondary                                          9 (20)              8 (17)

  Marital status, N (%)                                                                  

      Single                                                         8 (17%)             8 (17%)

      Married                                                        32 (67)             32 (67)

      Divorced                                                       2 (4)               2 (4)

      Widowed                                                        0 (0)               1 (2)

      Cohabitating                                                   5 (10)              5 (10)

  Employed, N (%)                                                    22 (47%)            27 (56%)

  Partner employed, N (%)                                            40 (93%)            38 (93%)

  Mean number of people in household,                                5.1                 2.8

  Mean Tanzanian shillings spent on food per household/day *(USD)*   6287 TSh (\$2.99)   5341 TSh\
                                                                                         (\$2.54)

  Daily activity level, N (%)                                                            

      Very Light                                                     0                   2

      Light                                                          32                  26

      Moderate                                                       14                  19

      Heavy                                                          0                   0

  Food Insecurity Score                                              6.6                 5.0

  Weight *(mean*, *kilograms)*                                       63.8                62.4

  BMI *(mean*, *kg/m*^*2*^*)*                                        25.8                25.3

  Mid-upper arm circumference *(mean*, *cm)*                         27.2                27.2

  Hematocrit (mean)                                                  29.1                28.8

  Albumin (mean)                                                     3.32                3.34

  CD4 count (mean/mm^3^)                                             394                 469

  N on Antiretroviral therapy (%)                                    38 (79%)            37 (77%)
  --------------------------------------------------------------------------------------------------

At baseline in the third trimester a total of 38/48 (79%) women in the MNS group and 37/48 (77%) women in the PCS group were on ART (p = 1.0) A total of 9/47 (19%) of women in the MNS group and 7/46 (15%) in the PCS group reported occasionally missing a day or more of ART during the third trimester (p = 0.82). A total of 19/29 (66%) women in the MNS group and 17/35 (49%) women in the PCS group reported remaining on ART at 3 months (p = 0.27). A total of 14/28 (50%) women in the MNS group and 18/34 (53%) women in the PCS group reported remaining on ART at 6 months (p = 1.0). At the time of delivery 44/48 (92%) infants in the MNS group and 42/48 (88%) infants in the PCS were on ART (p = 0. 74).

Dietary recall {#sec027}
--------------

Baseline dietary intakes were comparable in the two intervention groups ([Table 2](#pone.0201038.t002){ref-type="table"}). At the 2--4 week post-delivery home visit women in the PCS group had a daily energy intake 415 Kcal higher than the MNS group and a daily protein intake 22 gm higher than the MNS group. Compared to WHO recommendations these 2--4 week values represent a deficit of 81 Kcal and 6 gm protein in the PCS group and a deficit of 496 Kcal and 28 gm protein in the MNS group. Differences in dietary energy and protein intake between the two groups persisted through 6 months post-partum. Diarrhea, nausea, or vomiting were not reported by women in either group. Death or loss to follow-up at 6 months was 25% (12/48) in the MNS group and 15% (7/48) in the PCS group (p = 0.31). Information on causes of death in mothers and infants was not available.

10.1371/journal.pone.0201038.t002

###### Mean (sd) energy and protein intake of study subjects.

![](pone.0201038.t002){#pone.0201038.t002g}

                                MNS          PCS + MNS    p-value
  ----------------------------- ------------ ------------ ---------
  **Baseline**\*                                          
      **Kcal**                  2185 (721)   2312 (683)   0.39
      **Protein**               55 (30)      58 (23)      0.62
  **Pre-birth**\*\*                                       
      **Kcal**                  2161 (658)   2880 (591)   \<0.001
      **Protein**               52 (26)      85 (231)     \<0.001
  **Week 2--4 post delivery**                              
      **Kcal**                  2358 (677)   2773 (689)   0.007
      **Protein**               58 (20)      80 (27)      \<0.001
  **Month 3 post delivery**                                
      **Kcal**                  2462 (612)   2850 (712)   0.03
      **Protein**               60 (27)      80 (26)      0.004
  **Month 6 post delivery**                                
      **Kcal**                  2257 (616)   2896 (460)   \<0.001
      **Protein**               51 (16)      82 (17)      \<0.001

\* Data not available for 3 subjects at baseline and additional subjects during follow-up

\*\* Includes subjects who had been taking the supplement for at least one month

Note: Data and statistical significance similar when excluding women with twins

Study endpoints and anthropometry {#sec028}
---------------------------------

Primary and secondary endpoints are shown in [Table 3](#pone.0201038.t003){ref-type="table"}. Infant weights at 3 months did not differ between the two groups (primary endpoint). Among 52 women on ART at 3 months mean infant weight at 3 months was 5.41 in the MNS group and 5.81 kg in the PCS group (p = 0.08). Among 36 women not on ART at 3 months mean infant weight at 3 months was 6.0 kg in the MNS group and 5.6 kg in the PCS group (p = 0.22).

10.1371/journal.pone.0201038.t003

###### Infant weights and maternal BMI values.

![](pone.0201038.t003){#pone.0201038.t003g}

                                            MNS           PCS+MNS        P-value   Mean difference (sem)
  ----------------------------------------- ------------- -------------- --------- -----------------------
  **Infant weight (kg, mean, sd)**                                                 
  Birth, all infants                        3.01 (0.61)   3.17 (0.59)    0.21      0.16(0.13)
  Birth, no twins                           3.04 (0.60)   3.30 (0.57)    0.04      0.26 (0.13)
  Month 3, all infants\*                    5.99 (0.73)   5.63 (0.89)    0.07      -0.36 (0.20)
  Month 3, no twins                         6.05 (0.63)   5.77 (0.83)    0.14      -0.28 (0.19)
  Month 6, all infants                      7.32 (1.32)   6.92 (0.82)    0.13      -0.40 (0.22)
  Month 6, no twins                         7.42 (1.25)   6.99 (0.84)    0.12      -0.43 (0.23)
  **Infant z score (weight for length)**                                           
  Month 3, all infants                      0.23 (1.18)   0.24 (1.31)    0.96      0.01 (0.33)
  Month 3, no twins                         0.27 (1.11)   0.30 (1.34)    0.90      0.03 (0.31)
  Month 6, all infants                      0.15 (1.53)   -0.14 (1.08)   0.07      -0.29 (0.35)
  Month 6, no twins                         0.15 (1.51)   -0.10 (1.12)   0.07      -0.25 (0.43)
  **Maternal BMI (kg/m^2^, median)**                                               
      Baseline\^                            25.8          25.3           0.58      -0.5 (0.9)
      Post-delivery                         24.3          23.5           0.34      -0.8 (0.9)
      Month 3                               25.2          24.9           0.73      -0.3 (1.0)
      Month 6\*\*                           24.3          23.8           0.68      -0.5 (1.1)
  **Maternal MUAC (cm, mean)**                                                     
      Pre-birth                             27.2          27.2           0.97      -0.0 (0.8)
      Month 3                               27.8          27.3           0.56      -0.5 (0.9)
      Month 6\*\*                           28.0          27.9           0.88      -0.1 (1.1)
  **Maternal CD4 increase (cells/mm^3^)**                                          
      Month 6                               135           161            0.64      26 (41)

\* Primary study endpoint

\*\* Secondary study endpoint

MUAC = mid-upper arm circumference

Maternal BMI at 6 months did not differ between the two groups (secondary endpoint). Change in maternal BMI at 6 months did not differ between the two groups (data not shown). Trends in BMI differences at 6 months differed by ART status: for 38 mothers on ART median BMI was 25 in the MNS group and 22 in the PCS group (p = 0.07); for 39 mothers not on ART median BMI was 22 in the MNS group and 24 in the PCS group (p = 0.23). MUAC values were not significantly different at baseline or at 3 and 6 months. Additional anthropometric data will be the subject of a separate report on body composition.

Laboratory studies {#sec029}
------------------

There were no significant differences in CD4, albumin, hemoglobin or white blood count between the 2 groups at baseline or during follow up and no significant difference in change in of these laboratory values from baseline to 3 or 6 months between the two groups (data not shown). For CD4 count the mean increases at 6 months were 135/mm^3^ in the MNS group and 161/mm^3^ in the PCS group (p = 0.64) and for hematocrit 4.4 and 2.3 respectively (p = 0.16).

Infant HIV infection and mortality {#sec030}
----------------------------------

As shown in [Table 4](#pone.0201038.t004){ref-type="table"} the rate of infant HIV infection by age 15 months was 8.3% (4 of 48) in MNS group and 0% (0 of 48) in PCS group (p = 0.117, Fisher's exact test; p = 0.036, log-rank test). The 4 cases of HIV transmission included 2 cases confirmed by ELISA (one tested at 15 months per-protocol and one tested at 8 months during a terminal hospitalization) and 2 cases confirmed by Ministry of Health dried blood spot (DBS) PCR testing at 2--3 months. There were 7 infant deaths in each treatment group (p = 0.90)

10.1371/journal.pone.0201038.t004

###### Infant HIV infection.

![](pone.0201038.t004){#pone.0201038.t004g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study number   Group   Baseline Maternal CD4   Antiretroviral therapy   Infant\   Positive HIV test   Infant outcome                                   
                                                                          feeding                                                                        
  -------------- ------- ----------------------- ------------------------ --------- ------------------- ---------------- -------- ---------------------- --------------
  **4303**       MNS     121                     AZT NVP                  NVP       None                AZT 3TC NVP      Mixed    PCR 2 mos              Died 8 mos

  **4309**       MNS     624                     None                     AZT NVP   None                AZT 3TC NVP      Breast   ELIS 15 mos            Alive 15 mos

  **4383**       MNS     389                     AZT                      NVP       None                None             Breast   ELIS 8 mos             Died 10 mos

  **4388**       MNS     60                      AZT 3TC NVP              NVP       AZT 3TC NVP         AZT 3TC NVP      Breast   PCR 3 mos ELISA5 mos   Alive 15 mos
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

AZT = azidothymidine; ELISA = enzyme linked immunosorbent assay for HIV; Mixed = breast milk plus formula: NVP = nevirapine; PCR = dried blood spot polymerase chain reaction (PCR) for HIV

Discussion {#sec031}
==========

In the present study we found that a locally produced protein-calorie supplement was well-accepted and well-tolerated by HIV-infected lactating women in Tanzania who were not malnourished at baseline. The PCS led to a measurable increase in dietary energy and protein intake and erased the calculated baseline deficits compared to recommendations of the WHO. However, the PCS did not affect the primary endpoint of infant weight at 3 months or the secondary endpoint of maternal BMI at 6 months. However, HIV transmission was unexpectedly lower among infants of mothers who received the supplement.

Although not a primary study endpoint, birth weight was higher in the PCS group and significantly higher when twins were excluded from the analysis. Lower infant birth weight has been consistently associated with poorer health outcomes in children \[[@pone.0201038.ref026]\]. Higher birth weight in the intervention group may have been a result of the PCS providing higher energy and protein intake during the last trimester of pregnancy. The absence of an effect on infant weight at 3 months is consistent with maintenance of lactational capacity and thus protection of infant growth, in women not severely malnourished \[[@pone.0201038.ref027]\]. The absence of an effect on infant weight at 3 months could also be due to cultural practices ensuring that lactating women receive preferential access to food, though 24 hour recalls continued to show inadequate intakes in the MNS group.

Since all women in the trial were required to be enrolled in PMCT programs the trial was not powered to detect an effect of the PCS supplement on rates of mother-to-infant HIV transmission. However, HIV transmission rates were significantly lower in the PCS group despite similar, though low, overall rates of maternal ART at 3 and 6 months. Since HIV testing data and complete follow-up was not available on all infants we cannot exclude the possibility that this was a chance finding. However, mothers in the trial faithfully reported infant illness and outside HIV test results so we believe unreported infant HIV infections were unlikely. Maternal nutrition could have affected HIV transmission risk in several ways: through improved ART compliance, reduced ART side effects, reduction in mixed infant feeding, or improved breast milk characteristics. Limited data from this study do not support differences in ART compliance or side effects or differences in rates of mixed feeding.

The present study adds to available data on macronutrient supplementation for HIV-infected lactating women. In Malawi a lipid-based macronutrient supplement for HIV-infected lactating women had no effect on infant growth\[[@pone.0201038.ref028]\]. In another trial in Malawi, the Breastfeeding, Antiretrovirals and Nutrition (BAN) study HIV-infected mothers and their infants were randomly assigned to either receive a lipid based nutrient supplement (LNS) providing 700 calories and 20 grams of protein daily, or control. While the LNS reduced weight loss among HIV-infected breastfeeding women the supplement had no effect on infant growth \[[@pone.0201038.ref029], [@pone.0201038.ref030]\]. In the present study macronutrient supplementation did not have an effect on infant weight or maternal BMI.

This study has several limitations. The relatively small sample size could have prevented detection of a modest treatment effect. In addition it would not have been ethical to enroll and randomize women with baseline malnutrition, a group that would have been more likely to benefit from the intervention. The reported absence of nausea, vomiting or diarrhea in study subjects over 6 months is unexpected and may indicate a reluctance to admit these symptoms. Finally, without serial PCR testing on all infants we are unable to determine the timing of infant HIV infection. Breast milk transmission would have been possible for some of the 4 infections since 3 of the mothers were no longer on ART at 3 months.

In summary we found that a locally produced protein-energy supplement administered for 6 months to non-malnourished lactating women with inadequate pre-study dietary intake did not have an effect on infant weight at 3 months or maternal BMI at 6 months. An unexpected decrease in the rate of HIV infection among infants of mothers receiving the supplement remains unexplained.
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